Sign In
Buy GBT
$68.49
+0 (+0%)
At Close: Jan 27, 2023
GBT Announces New Employment Inducement Grants
12:00pm, Wednesday, 08'th Jul 2020
SOUTH SAN FRANCISCO, Calif., July 08, 2020 -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on July 1, 2020, the compensation committee of GBT’s.
NASDAQ Starts Second Half with a New Closing High
12:00am, Thursday, 02'nd Jul 2020
Stocks Analysis by Zacks Investment Research covering: Boeing Co, Bed Bath & Beyond Inc, Pfizer Inc, Micron Technology Inc. Read Zacks Investment Research's latest article on Investing.com
Children below age 12 with sickle cell disorder can live normal life - Expert
03:15am, Wednesday, 01'st Jul 2020
A medical expert, Dr David Ajibade, says children below the age of 12 with sickle cell disorder, can live an almost normal life, if proper care
Apple Tree Partners Founds Nine Square Therapeutics to Pioneer Novel Treatments for Movement Disorders
12:00am, Wednesday, 01'st Jul 2020
New company, co-founded with UCSF scientists and being incubated in San Francisco, will apply computational sciences and machine learning to accelerate drug discovery in Parkinson’s disease, ALS, es
- Vanguard News NGOs raise alarm over rising sickle cell cases
10:15pm, Sunday, 28'th Jun 2020
As the world marked 2020 world sickle cell disorder, SCD, day, a coalition of NGOs has decried the alarming rate of cases in the country.
2 Top Gene-Editing Stocks to Buy Right Now | The Motley Fool
11:36am, Sunday, 28'th Jun 2020
Both of these biotech companies recently released encouraging data from clinical trials.
Sickle Cell Disease: All you need to know
06:39am, Saturday, 27'th Jun 2020
Sickle cell disease can lead to a lot of complication, including stroke, acute chest syndrome, pulmonary hypertension, organ damage, blindness, leg ulcers, among others.
The best free music downloader 2020
02:56pm, Friday, 26'th Jun 2020
Find and download new songs, or grab old favorites
La société prévoit de demander une autorisation de mise sur le marché complète pour Oxbryta pour le traitement de l'anémie hémolytique dans la...
GBT Awards $250,000 in ACCEL Grants to Advance Access to Care for People Living with Sickle Cell Disease
05:00pm, Thursday, 25'th Jun 2020
SOUTH SAN FRANCISCO, Calif., June 25, 2020 -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that five U.S. nonprofit organizations serving the sickle cell.
Global Blood to Seek Approval of Oxbryta in Europe for SCD
12:59pm, Thursday, 25'th Jun 2020
Global Blood (GBT) plans to seek approval for Oxbryta tablets to treat hemolytic anemia in SCD patients aged 12 years and older in Europe.
Global Blood Therapeutics (GBT) Gets a Buy Rating from William Blair - Markets
07:53pm, Wednesday, 24'th Jun 2020
William Blair analyst Raju Prasad maintained a Buy rating on Global Blood Therapeutics (GBT – Research Report) today. The company’s
GBT Announces Plans to Seek Regulatory Approval for Oxbryta® (voxelotor) to Treat Sickle Cell Patients in Europe
12:30pm, Wednesday, 24'th Jun 2020
An oral, once daily therapy, Oxbryta directly inhibits hemoglobin polymerization, the root cause of the sickling and destruction of red blood cells in SCD. The sickling process causes hemolytic anemi
Editas Medicine Falling 6% In Pre-Market On Offer Pricing
09:12am, Wednesday, 24'th Jun 2020
Shares in Editas Medicine (EDIT) are falling 6% in Wednesday’s pre-market trading after the company announced a price of $31.25 per share for its
Understanding plight of persons living with Sickle cell disease
12:32am, Tuesday, 23'rd Jun 2020
Sefiat (not real name), became rebellious to her parents because she could no longer bear the pain she was suffering. She began to question why she was treated differently from her other siblings;�
